MRC1 and carcinoma: A detectable second hit (LOH or a non‐synonymous somatic nucleotide variant) for inactivation of the MMR gene in question was present in 73% (16/22) and 86% (36/42) of hyperplasia and carcinoma samples, respectively (Table 1).